Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:item
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Matrix_Gla-protein
gptkb:Ergocalciferol |
| gptkbp:appointed_by |
topical treatment
oral supplement |
| gptkbp:clinical_trial |
chronic kidney disease
psoriasis hypoparathyroidism |
| gptkbp:discovered_by |
1970s
Michael F. Holick |
| gptkbp:dissolved |
lipid-soluble
|
| gptkbp:ecological_role |
bone health
calcium homeostasis |
| gptkbp:excretion |
urine
bile |
| gptkbp:function |
regulates calcium levels
|
| gptkbp:has_weakness |
osteomalacia
rickets |
| https://www.w3.org/2000/01/rdf-schema#label |
calcitriol
|
| gptkbp:influences |
apoptosis
cell differentiation cell proliferation immune function |
| gptkbp:ingredients |
C27 H44 O3
|
| gptkbp:interacts_with |
vitamin D receptors
nuclear receptors |
| gptkbp:mass |
416.64 g/mol
|
| gptkbp:metabolism |
hydroxylation
|
| gptkbp:previous_name |
(3 S,5 Z,7 E)-9,10-secocholesta-5,7,10(19)-triene-1,3-diol
|
| gptkbp:produced_by |
cholecalciferol
|
| gptkbp:production_location |
gptkb:skincare_product
kidney |
| gptkbp:products |
ergocalciferol
calcidiol |
| gptkbp:regulates |
gene expression
|
| gptkbp:role |
gptkb:item
|
| gptkbp:side_effect |
nausea
vomiting weakness hypercalcemia hyperphosphatemia |
| gptkbp:social_responsibility |
gptkb:healthcare_organization
gptkb:Company autoimmune diseases cardiovascular diseases osteoporosis |
| gptkbp:storage |
fatty tissues
|
| gptkbp:targets |
gptkb:healthcare_organization
kidney intestine |
| gptkbp:type_of |
32222-06-3
|